(Q33402388)

English

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

0 references

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

object named as

D Cunningham

3

0 references

author name string

I Chau

1

1 reference

Europe PubMed Central

26 July 2017

A R Norman

2

1 reference

Europe PubMed Central

26 July 2017

J Oates

4

1 reference

Europe PubMed Central

26 July 2017

R Hawkins

5

1 reference

Europe PubMed Central

26 July 2017

T Iveson

6

1 reference

Europe PubMed Central

26 July 2017

M Nicolson

7

1 reference

Europe PubMed Central

26 July 2017

P Harper

8

1 reference

Europe PubMed Central

26 July 2017

M Seymour

9

1 reference

Europe PubMed Central

26 July 2017

T Hickish

10

1 reference

Europe PubMed Central

26 July 2017

publication date

22 January 2009

1 reference

Europe PubMed Central

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

26 July 2017

20

1 reference

Europe PubMed Central

26 July 2017

5

1 reference

Europe PubMed Central

26 July 2017

885-891

1 reference

Europe PubMed Central

26 July 2017

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Epidemiology and pathogenesis of esophageal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN716

21 January 2018

Identifiers

10.1093/ANNONC/MDN716

1 reference

Europe PubMed Central

26 July 2017

release_6x6xveyyvffapmldz52djccriy

1 reference

https://api.fatcat.wiki/v0/release/6x6xveyyvffapmldz52djccriy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33402388&oldid=1954446995"